Emily Paprocki

Emily Paprocki

Auto-generated profile, based on publicly available information

Emily Paprocki

Division of Pediatric Endocrinology and Diabetes, Children's Mercy Kansas City University of Missouri‐Kansas City Kansas City Missouri USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2022 in Nature and Science of Sleep
Verified
Journal Article
Open access
PDF file
DIDavid G Ingram
David G Ingram
JAJill M Arganbright
Jill M Arganbright
EPEmily Paprocki
Emily Paprocki
KHKelsee Halpin
Kelsee Halpin
Children with Prader-Willi syndrome (PWS) face a multitude of potential health challenges including life-threatening obesity, endocrinopathies, behavioral and emotional dysregulation, developmental delays, and sleep disorders. In the current perspective piece, we provide a focused review of the condition’s etiology and clinical findings, as well as a more in-depth discussion of sleep disorders frequently associated with PWS. In particular, we highlight and discuss difficult clinical scenarios frequently encountered by the pediatric sleep physician caring for this patient population, including diagnosis and treatment of complex sleep-related breathing disorders, considerations for sleep apnea surgery, the interplay between growth hormone and sleep apnea, diagnostic challenges in hypersomnia/narcolepsy, and current and emerging therapies for hypersomnia/narcolepsy. Overall, although there are many areas that need further research, sleep disorders remain a fruitful target for improving quality of life of children with PWS and their families.

7 May 2019 in Journal of the Endocrine Society
Verified
Journal Article
Open access
PDF file
EPEmily Paprocki
Emily Paprocki
RBRomina L Barral
Romina L Barral
HBHeidi Vanden Brink
Heidi Vanden Brink
MLMarla Lujan
Marla Lujan
TBTania S Burgert
Tania S Burgert
Type A insulin resistance (IR) is caused by heterozygous mutations in the insulin receptor gene. It presents with mild acanthosis nigricans, severe IR, and hyperandrogenism in the absence of obesity or lipodystrophy. Treatment aims to improve insulin sensitivity and decrease androgens. An adolescent female was evaluated for secondary amenorrhea and prominent hirsutism. She had a normal BMI and laboratories revealed elevated LH to FSH ratio (LH 11.6 mIU/mL, FSH 4.2 mIU/mL), testosterone 96 ng/dL (<50), free testosterone 2.21 ng/dL (A(pGly1032Asp)). After standard treatment for hirsutism and hyperinsulinism failed, a trial of GnRH agonist therapy improved hyperandrogenism and reduced ovarian size while severe IR persisted. We describe an adolescent with Type A IR who experienced resolution of clinical and biochemical hyperandrogenism during GnRH agonist treatment. Given the patient’s marked reduction in testosterone and hirsutism despite persistent hyperinsulinism, this case challenges the idea that insulin increases steroidogenesis independently of gonadotropin effect. GnRH agonist therapy should be considered in the treatment of hyperandrogenism in severe cases of IR.

26 June 2023 in Case Reports in Endocrinology
Verified
Journal Article
Open access
PDF file
EWErica Wee
Erica Wee
JHJohn Herriges
John Herriges
KDKavitha Dileepan
Kavitha Dileepan
STSarah Tsai
Sarah Tsai
JAJoseph T. Alaimo
Joseph T. Alaimo
EPEmily Paprocki
Emily Paprocki
Hypoglycemia is concerning for neurological complications in infants and children. Determining the cause of hypoglycemia is essential in providing appropriate treatment. Hyperinsulinism and growth hormone deficiency are known causes of hypoglycemia but are not commonly found together. We report a 4-month-old boy who presented with severe hypoglycemia and was found to have both hyperinsulinism and growth hormone deficiency. Treatment with both recombinant human growth hormone and diazoxide led to blood glucose normalization. Subsequently, he was found to have a genetic diagnosis of 20p11.22p11.21 deletion. 20p11 deletions have been associated with hypopituitarism, most commonly seen in growth hormone deficiency causing hypoglycemia. This case is one of a few to report hyperinsulinism as a manifestation of this deletion.

1 May 2021 in Journal of the Endocrine Society
Verified
Journal Article
Open access
PDF file
EPEmily Paprocki
Emily Paprocki
YYYun Yan
Yun Yan
Brian R. LeeBrian R. Lee
Brian R. Lee
MBMitchell Barnes
Mitchell Barnes
FLFrancesco De Luca
Francesco De Luca
KHKelsee Halpin
Kelsee Halpin
Background: Pediatric type 2 diabetes (T2D) has increased in prevalence as childhood obesity rates climb. More youth are being referred to pediatric endocrinology due to the concern for developing T2D, yet prediction of which children will progress to overt T2D is challenging. We describe a single center experience with pediatric prediabetes referrals and trends in HbA1c change. Methods: Retrospective review of new patients seen at a Type 2 Diabetes Prevention (T2DP) Clinic July 2015 - December 2019. All children referred to T2DP Clinic have an elevated BMI and findings of insulin resistance/prediabetes/early T2D. They are evaluated by pediatric endocrinology providers and dieticians at each visit. The outcome of interest was categorical HbA1c change between patients’ initial and most recent T2DP Clinic visit. Only HbA1c measurements conducted at the study site were included to address inconsistencies in lab assays. HbA1c at the initial visit was categorized into 3 groups: 1) < 5.7%; 2) 5.7 to <6.5%; 3) 6.5% to group 2) between initial and most recent HbA1c. Comparisons between groups were made using ANOVA and Fisher’s exact tests. Results: Among 297 patients seen for an initial visit, mean BMI z-score was 2.3 and body fat percentage was 44%. High blood pressure occurred in 47%, high ALT in 24%, low HDL in 14%. Prevalence of initial HbA1c < 5.7%, 5.7 to < 6.5%, and 6.5% to < 8.5% was 46%, 42%, and 12%, respectively. One-third (31%) were prescribed metformin at their initial visit. Only 63 patients (21%) had 2 or more visits in the T2DP Clinic with study site HbA1c data available. Of those 63 patients, mean age at initial visit was 12.5 years, BMI z-score 2.0, and body fat 46%. Most patients were female (68%) with public insurance (70%). Race/ethnicity was 35% black, 29% white, 30% Hispanic. Mean time between initial and most recent HbA1c was 11.9 months. Assessment of categorical HbA1c change showed 14% of patients with progression (n=9), 65% stable (n=41), and 21% with regression (n=13). Female sex, ALT elevation, HbA1c, fasting glucose were found to be statistically different between the groups at baseline (p < 0.05). Age, race/ethnicity, BMI, body fat percentage, elevated blood pressure, lipid profile, 120-minute glucose on OGTT, and metformin use were not different between the groups. Conclusions. Only 14% of children who presented for follow up in our T2DP clinic demonstrated progression in HbA1c. Risk factors for those who progress include female sex and ALT elevation. Further development of predictive models to identify this high-risk population who will progress is necessary. Retaining consistent follow up in pediatric prediabetes clinics presents a challenge.

13 October 2018 in Journal of Diabetes Science and Technology
Verified
Journal Article
Closed access
EPEmily Paprocki
Emily Paprocki
VSVincent Staggs
Vincent Staggs
SPSusan Patton
Susan Patton
MCMark Clements
Mark Clements

1 May 2021 in Journal of the Endocrine Society
Verified
Journal Article
Open access
PDF file
BHBenjamin Donald Hoag
Benjamin Donald Hoag
MKMichelle Knoll
Michelle Knoll
EPEmily Paprocki
Emily Paprocki
Hyperglycemic hyperosmolar state (HHS) is rare in pediatrics, particularly in patients with antibody positive diabetes mellitus (DM). Recent literature has implicated COVID-19 in the reported increase in new-onset DM cases, as well as mixed diabetic ketoacidosis (DKA) and HHS cases, however a rise in HHS cases alone has not been well reported [1,2]. We noted an anecdotal increase in the frequency of HHS cases in our pediatric tertiary care center following the onset of the global COVID-19 pandemic. To investigate further, a retrospective chart review evaluating all patients with DM admitted in the first 6 months of 2019 and the first 6 months of 2020 was conducted. A diagnosis of HHS was defined as a blood glucose over 600 mg/dL with a serum osmolality (calculated or measured) greater than 320 mOsm/kg on initial laboratory evaluation. Patients with DKA, defined as a serum bicarbonate level less than 16 mmol/L with evidence of significant ketosis (serum ketones greater than 3 mmol/L), were excluded from the study. During the first 6 months of 2019, 1 patient met inclusion criteria. However, the diagnosis of HHS was complicated by a concurrent diagnosis of diabetes insipidus, which may have contributed to the hyperosmolar state, and a nonketotic lactic acidosis. Five HHS cases were noted in the first 6 months of 2020, 4 of which occurred in May and June. For the 2020 HHS cohort, the average patient age ± SD was 12 ± 3.34 years. The mean ± SD laboratory values included bicarbonate 18.2 ± 1.64 mmol/L, serum blood glucose 776.8 ± 30.75 mg/dL, calculated serum osmolality 328 ± 4.18 mOsm/kg, and HgA1C 12.72 ± 1.16%. All 5 patients in the 2020 cohort had new-onset DM, with 4 of the 5 patients having at least 1 positive DM antibody (GAD antibodies were positive in 3, ICA/IA-2 antibodies in 2, and Zinc Transporter 8 antibodies in 1). No patients displayed COVID-19 symptoms, and only 1 patient was tested for COVID-19 by PCR, which returned negative. However, SARS-CoV2 antibody testing was not available, and it is unknown if these patients had prior COVID-19 illness. In conclusion, we noted an increased incidence of HHS at our hospital, particularly among new-onset, antibody positive DM patients during the initial months of the COVID-19 pandemic. Further study and investigation are needed to determine the cause of this increased local incidence, and if infectious, social, or economic influences related to the COVID-19 pandemic contributed. References: [1] Chan, K.H., et al., Clinical characteristics and outcome in patients with combined diabetic ketoacidosis and hyperosmolar hyperglycemic state associated with COVID-19: A retrospective, hospital-based observational case series. Diabetes Res Clin Pract, 2020. 166: p. 108279. [2] Unsworth, R., et al., New-Onset Type 1 Diabetes in Children During COVID-19: Multicenter Regional Findings in the U.K. Diabetes Care, 2020.